Key result
Minimally invasive direct coronary artery bypass showed similar 5-year survival compared to drug-eluting stents (HR 0.95, P=0.89), but was associated with a lower rate of MACCE (HR 0.32, P<0.0001).
Why the study?
Does first-generation drug-eluting stent implantation improve 5-year survival and reduce MACCE compared to minimally invasive direct coronary artery bypass in patients with isolated left anterior descending artery disease?
Cohort (n=456)
Does first-generation drug-eluting stent implantation improve 5-year survival and reduce MACCE compared to minimally invasive direct coronary artery bypass in patients with isolated left anterior descending artery disease?
Hazard Ratio: 0.95
p-value: p=0.89
In patients with isolated LAD disease, MIDCAB and first-generation DES offer similar 5-year survival, but MIDCAB significantly reduces the need for repeat revascularization and MACCE.
OBJECTIVES: The spread of drug-eluting stents (DES) has reduced the incidence of early restenosis following percutaneous coronary interventions (PCI). Meanwhile, development of minimally invasive coronary artery bypass surgery (MIDCAB) has offered a valuable alternative to conventional sternotomy with preservation of the benefit of the internal mammary artery use. Therefore, the revascularization of the left anterior descending (LAD) artery is suitable for both techniques. However, few data with long-term comparison of these two techniques exist. METHODS: Prospective data were collected for 456 patients undergoing isolated LAD revascularization between 1997 and 2011. Two hundred and sixty patients were treated with MIDCAB and 196 with first-generation DES implantation. A propensity score model was created to adjust for 19 relevant confounding variables. Primary and secondary end-points were, respectively, 5-year survival and freedom from major adverse cerebro-cardiovascular events (MACCE). RESULTS: Both groups were similar in age, EuroSCORE and mean duration of follow-up. Five-year survival was similar after MIDCAB or DES (hazard ratio (HR): 0.95; P = 0.89). Freedom from MACCE was significantly in favour of the MIDCAB group (HR: 0.32, P < 0.0001), mainly triggered by high subsequent need for revascularization of the targeted vessel in the DES group (HR: 0.17, P < 0.0001). CONCLUSIONS: MIDCAB and DES implantation showed similar rates of survival but despite an expected lower rate of reintervention on the targeted vessel with DES use, a highly significant higher MACCE rate was observed in the PCI group at 5-year follow-up.
No takes yet. Share an insight, caveat, or question.
Etienne et al. (2013) conducted a cohort in Left anterior descending artery disease (n=456). Minimally invasive direct coronary artery bypass (MIDCAB) vs. First-generation drug-eluting stents (DES) implantation was evaluated on 5-year survival (HR 0.95, p=0.89). Minimally invasive direct coronary artery bypass showed similar 5-year survival compared to drug-eluting stents (HR 0.95, P=0.89), but was associated with a lower rate of MACCE (HR 0.32, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: